DexCom Analyst Price Targets - Benzinga

DexCom Inc

DXCMNASDAQ

Trade with Public

Trade with Public

$84.46

-4.02-4.54%

Últ. Act.: Nov 6, 4:23 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

DexCom Analyst Price Targets - Benzinga

DexCom Analyst Price Targets

Wall Street analyst price targets and consensus rating for DexCom (DXCM).

Price Target Range — 9 Quarters

Analyst Consensus — 26 Analysts

1S.Buy

23Buy

2Hold

Consensus RatingBuy# Analysts26Avg. Consensus PT$92Upside to Avg. PT+9.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	UBS	Patrick Wood	PT Raise	Buy	$102→$107
Oct 30, 2026	Canaccord Genuity	William Plovanic	PT Raise	Buy	$90→$97
Oct 30, 2026	JP Morgan	Robbie Marcus	PT Raise	Neutral	$82→$85
Oct 30, 2026	Barclays	Christopher Pasquale	PT Raise	Overweight	$115→$120
Oct 30, 2026	StoneX	Bruce D. Jackson	PT Raise	Buy	$82→$93
Oct 12, 2026	BTIG	Ryan Zimmerman	PT Raise	Buy	$90→$96
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Overweight	$115
Oct 1, 2026	RBC Capital	Kendall Au	PT Raise	Outperform	$90→$105
Sep 18, 2026	Truist Securities	Richard Newitter	PT Raise	Buy	$93→$102
Sep 18, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$95
Aug 4, 2026	Argus Research	Steve Silver	PT Raise	Buy	$86→$96
Aug 3, 2026	Canaccord Genuity	William Plovanic	PT Raise	Buy	$82→$90
Jul 31, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$84→$88
Jul 31, 2026	RBC Capital	Kendall Au	PT Raise	Outperform	$85→$90
Jul 31, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$90→$95
Jul 31, 2026	JP Morgan	Robbie Marcus	PT Raise	Neutral	$65→$82
Jul 31, 2026	Piper Sandler	Matt O'Brien	PT Raise	Overweight	$88→$95
Jul 31, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$85→$90
Jul 31, 2026	Stifel	Jonathan Block	PT Raise	Buy	$90→$95
Jul 31, 2026	Benchmark	Bruce D. Jackson	PT Raise	Buy	$77→$82

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $97.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on DexCom, Raises Price Target to $85

JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the price target from $82 to $85.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on DexCom, Raises Price Target to $120

Barclays analyst Christopher Pasquale maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $115 to $120.

Benzinga Newsdesk

PRO
StoneX Maintains Buy on DexCom, Raises Price Target to $93

StoneX analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $93.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on DexCom, Raises Price Target to $96

BTIG analyst Ryan Zimmerman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $96.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $115

Barclays analyst Christopher Pasquale initiates coverage on DexCom (NASDAQ:DXCM) with a Overweight rating and announces Price Target of $115.

Benzinga Newsdesk